Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496

Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection.

Li, C., & Wong, W. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.31 · Cited by 3,133

Trastuzumab — Mechanism of Action and Use in Clinical Practice

Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,640

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627

Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)

Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 886

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

Nahta, R., Yuan, L. X. H., Zhang, B., Kobayashi, R., & Esteva, F. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3841 · Cited by 793

Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy

Weinstein, I. B., & Joe, A. K. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0558 · Cited by 739

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer

Valabrega, G., Montemurro, F., & Aglietta, M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl475 · Cited by 636

Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network

Ritter, C. A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J. A., & Arteaga, C. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0701 · Cited by 497

Systematic analysis of gene expression pattern in has-miR-760 overexpressed resistance of the MCF-7 human breast cancer cell to doxorubicin

Lv, J., Fu, Z., Shi, M., Xia, K., Ji, C., Xu, P., Lv, M., Pan, B., Dai, L., & Xie, H. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.11.028 · Cited by 31

(−)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo

Siddique, A. B., Ebrahim, H. Y., Akl, M. R., Ayoub, N. M., Goda, A. A., Mohyeldin, M. M., Nagumalli, S. K., Hananeh, W. M., Liu, Y., Meyer, S. A., et al. (2019) · Nutrients · doi:10.3390/nu11020412 · Cited by 31

MET deregulation in breast cancer.

Minuti, G., & Landi, L. M. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.06.22 · Cited by 32

Significant survival impact of MACC1 polymorphisms in HER2 positive breast cancer patients

Muendlein, A., Hubalek, M., Geller-Rhomberg, S., Gasser, K., Winder, T. L., Drexel, H., Decker, T. W., Mueller‐Holzner, E., Chamson, M., Marth, C., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.05.007 · Cited by 31

Predictive Biomarkers in the Treatment of Her2-Positive Breast Cancer: An Ongoing Challenge

Triulzi, T., Bianchi, G., & Tagliabue, E. (2016) · Future Oncology · doi:10.2217/fon-2015-0025 · Cited by 31

Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells

Huang, W., Hung, C., Wei, C., Chen, T.-M., Chien, P., Pan, H., Lin, Y.-M., & Chen, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.11471 · Cited by 32

Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer

McGivern, N., Helali, A. E., Mullan, P. B., McNeish, I. A., Harkin, D. P., Kennedy, R. D., & McCabe, N. (2017) · Oncotarget · doi:10.18632/oncotarget.23524 · Cited by 30

PKC-mediated phosphorylation and activation of the MEK/ERK pathway as a mechanism of acquired trastuzumab resistance in HER2-positive breast cancer

Scerri, J., Scerri, C. A., Schäfer-Ruoff, F., Fink, S., Templin, M. F., & Grech, G. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1010092 · Cited by 30

γ-Tocotrienol inhibits HGF-dependent mitogenesis and Met activation in highly malignant mammary tumour cells

Ayoub, N. M., Bachawal, S. V., & Sylvester, P. W. (2011) · Cell Proliferation · doi:10.1111/j.1365-2184.2011.00785.x · Cited by 30

SH3BGRL confers innate drug resistance in breast cancer by stabilizing HER2 activation on cell membrane

Li, H., Zhang, M., Wei, Y., Haider, F., Lin, Y., Guan, W. X., Liu, Y., Zhang, S., Yuan, R., Yang, X., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01577-z · Cited by 29

Challenges and resistance mechanisms to EGFR targeted therapies in head and neck cancers and breast cancer: Insights into RTK dependent and independent mechanisms

Shyamsunder, S., Lu, Z., Takiar, V., & Waltz, S. E. (2025) · Oncotarget · doi:10.18632/oncotarget.28747 · Cited by 28

H2O2 induces nuclear transport of the receptor tyrosine kinase c-MET in breast cancer cells via a membrane-bound retrograde trafficking mechanism

Chen, M., Du, Y., Sun, L., Hsu, J. L., Wang, Y.-H., Gao, Y., Huang, J., & Hung, M. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005953 · Cited by 28

Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas

Schwartz, H., Scroggins, B., Zuehlke, A. D., Kijima, T., Beebe, K. E., Mishra, A., Neckers, L., & Prince, T. L. (2015) · Cell Stress and Chaperones · doi:10.1007/s12192-015-0604-1 · Cited by 27

The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer

Zanini, E., Louis, L. S., Antony, J., Karali, E., Okon, I. S., McKie, A. B., Vaughan, S., El-Bahrawy, M. A., Stebbing, J., Recchi, C., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0081 · Cited by 27

A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy

Claus, J., Patel, G. S., Ng, T., & Parker, P. J. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140043 · Cited by 26

Analysis of the Effect of Increased α2,3-Sialylation on RTK Activation in MKN45 Gastric Cancer Spheroids Treated with Crizotinib

Balmaña, M., Diniz, F., Feijão, T., Barrias, C. C., Mereiter, S., & Reis, C. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030722 · Cited by 27

STAT3 mediated upregulation of C-MET signaling acts as a compensatory survival mechanism upon EGFR family inhibition in chemoresistant breast cancer cells

Zhu, Y., Zhang, H., Han, X., Wang, Z., Cui, Y., Tian, R., Wang, Z., Han, B., Tian, J., Zhang, F., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.07.048 · Cited by 26

Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer

Madrid-Paredes, A., Cañadas‐Garre, M., Sánchez–Pozo, A., & Calleja‐Hernández, M. Á. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3578-x · Cited by 26

c-Jun N-terminal Kinase 2 Regulates Multiple Receptor Tyrosine Kinase Pathways in Mouse Mammary Tumor Growth and Metastasis

Nasrazadani, A., & Berg, C. L. V. D. (2011) · Genes & Cancer · doi:10.1177/1947601911400901 · Cited by 25

Transcriptional repression of HER2 by ANO1 Cl− channel inhibition in human breast cancer cells with resistance to trastuzumab

Fujimoto, M., Inoue, T., Kito, H., Niwa, S., Suzuki, T., Muraki, K., & Ohya, S. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.11.033 · Cited by 26

Current Targeted Therapies in HER2-Positive Gastric Adenocarcinoma

Curea, F., Hebbar, M., Ilie, S. M., Bacinschi, X. E., Trifanescu, O. G., Botnariuc, I., & Anghel, R. M. (2017) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2017.2249 · Cited by 26

A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study

Ocaña, A., Gil-Martín, M., Martín, M., Rojo, F., Antolín, S., Guerrero, Á., Trigo, J. M., Muñoz-Mateu, M., Pandiella, A., Gonzalo, N., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17113 · Cited by 25

Therapeutic strategies for afatinib‐resistant lung cancer harboring HER 2 alterations

Torigoe, H., Shien, K., Takeda, T., Yoshioka, T., Namba, K., Sato, H., Suzawa, K., Yamamoto, H., Soh, J., Sakaguchi, M., et al. (2018) · Cancer Science · doi:10.1111/cas.13571 · Cited by 25

Significance of PD‑L1 clones and C‑MET expression in hepatocellular carcinoma

Chun, H. W., & Hong, R. (2019) · Oncology Letters · doi:10.3892/ol.2019.10222 · Cited by 25

Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma

de Silva, N., Schulz, L., Paterson, A., Qain, W., Secrier, M., Godfrey, E. M., Cheow, H., O’Donovan, M., Lao‐Sirieix, P., Jobanputra, M., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.342 · Cited by 25

Chapter 1 The Function, Proteolytic Processing, and Histopathology of Met in Cancer

Hanna, J. A., Bordeaux, J., Rimm, D. L., & Agarwal, S. (2009) · Advances in cancer research · doi:10.1016/s0065-230x(09)03001-2 · Cited by 25

Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study

Campiglio, M., Bufalino, R., Sandri, M. F., Ferri, E., Aiello, R. A., Matteis, A. D., Mottolese, M., Placido, S. D., Querzoli, P., Jirillo, A., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1484-4 · Cited by 24

Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas

Li, Y., Gao, L., Ma, D., Qiu, T., Li, W., Li, W., Guo, L., Xing, P., Liu, B., Deng, L., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.06.001 · Cited by 24

AXL – a new player in resistance to HER2 blockade

Adam‐Artigues, A., Arenas, E. J., Arribas, J., Prat, A., & Cejalvo, J. M. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102639 · Cited by 24

Current Development of Monoclonal Antibodies in Cancer Therapy

Parakh, S., King, D., Gan, H. K., & Scott, A. M. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-23765-3_1 · Cited by 25

Biologicals to direct nanotherapeutics towards HER2-positive breast cancers

Kumar, G., Nandakumar, K., Mutalik, S., & Rao, C. M. (2020) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2020.102197 · Cited by 24

Abl Kinases Regulate HGF/Met Signaling Required for Epithelial Cell Scattering, Tubulogenesis and Motility

Li, R., Knight, J. F., Park, M., & Pendergast, A. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124960 · Cited by 24

Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth

Keller, M., Rohlf, K., Glotzbach, A., Leonhardt, G., Lüke, S., Derksen, K., Demirci, Ö., Göçener, D., Alwahsh, M., Lambert, J., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02578-w · Cited by 23

Resistance to HER2 inhibitors: Is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation

Campone, M., Juin, P. P., André, F., & Bachelot, T. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.04.012 · Cited by 23

The Met tyrosine kinase receptor as a therapeutic target and a potential cancer stem cell factor responsible for therapy resistance

Miękus, K. (2016) · Oncology Reports · doi:10.3892/or.2016.5297 · Cited by 23

O‐Linked Triazolotriazines: Potent and Selective c‐Met Inhibitors

Chen, F., Wang, Y., Ai, J., Zhan, Z., Lv, Y., Liang, Z. T., Luo, C., Mei, D.-S., Geng, M., & Duan, W. (2012) · ChemMedChem · doi:10.1002/cmdc.201200145 · Cited by 23

p95HER2 Truncated Form in Resected Non-small Cell Lung Cancer

Cappuzzo, F., Cho, Y. G., Sacconi, A., Alì, G., Siclari, O., Incarbone, M., Destro, A., Terracciano, L., Fontanini, G., Marchetti, A., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318249e13f · Cited by 22

Silencing Kinase-Interacting Stathmin Gene Enhances Erlotinib Sensitivity by Inhibiting Ser10 p27 Phosphorylation in Epidermal Growth Factor Receptor–Expressing Breast Cancer

Zhang, D., Tari, A. M., Akar, U., Arun, B., LaFortune, T. A., Nieves-Alicea, R., Hortobágyi, G. N., & Ueno, N. T. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0362 · Cited by 22

Emerging insights into mechanisms of trastuzumab resistance in HER2-positive cancers

Wu, X., Huang, S., He, W., & Song, M. L. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110602 · Cited by 23

A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

Fan, X., Brezski, R. J., Deng, H., Dhupkar, P. M., Shi, Y., Gonzalez, A. O., Zhang, S., Rycyzyn, M. A., Strohl, W. R., Jordan, R. E., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0715 · Cited by 21

Targeted dual degradation of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models

Yang, L., Bhattacharya, A., Peterson, D. L., Li, Y., Liu, X., Marangoni, E., Robila, V., & Zhang, Y. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101078 · Cited by 20

Erk2 but not Erk1 regulates crosstalk between Met and EGFR in squamous cell carcinoma cell lines

Gusenbauer, S., Zanucco, E., Knyazev, P. G., & Ullrich, A. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0319-z · Cited by 20

Current approaches to the management of Her2-negative metastatic breast cancer

Gogineni, K., & DeMichele, A. M. (2012) · Breast Cancer Research · doi:10.1186/bcr3064 · Cited by 20

The Actual Role of Receptors as Cancer Markers, Biochemical and Clinical Aspects: Receptors in Breast Cancer

Brennan, M., & Lim, B. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-7215-0_20 · Cited by 20

Trastuzumab Resistance: Role for Notch Signaling

Mehta, K., & Osipo, C. (2009) · The Scientific World JOURNAL · doi:10.1100/tsw.2009.166 · Cited by 20

Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer

Creedon, H., Byron, A., Main, J., Hayward, L., Klinowska, T. C. M., & Brunton, V. G. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140109 · Cited by 19

Advances and Future Directions in the Targeting of HER2-positive Breast Cancer: Implications for the Future

Subbiah, I. M., & Gonzalez-Angulo, A. M. (2013) · Current Treatment Options in Oncology · doi:10.1007/s11864-013-0262-4 · Cited by 19

Tumour angiogenesis and c‐Met pathway activation – implications in breast cancer

Mitra, S., Bal, A., Kashyap, D., Kumar, S., Shrivastav, S., Das, A., & Singh, G. (2020) · Apmis · doi:10.1111/apm.13031 · Cited by 19

Dual membrane receptor degradation via folate receptor targeting chimera

Wang, Z., Li, Z., Hogstrom, J. M., Inuzuka, H., Jing, R., Yan, P., Hou, T., Qi, Y., Huang, D., Wang, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63882-5 · Cited by 18

Role of c-mesenchymal–epithelial transition pathway in gastric cancer

Fioroni, I., Dell’Aquila, E., Pantano, F., Intagliata, S., Caricato, M., Vincenzi, B., Coppola, R., Santini, D., & Tonini, G. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1037739 · Cited by 18

Combinatorial approaches targeting the EGFR family and c-Met in SCCHN

Wang, D., Lu, Y., Nannapaneni, S., Griffith, C. C., Steuer, C. E., Qian, G., Wang, X., Chen, Z., Patel, M. R., El‐Deiry, M. W., et al. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.105074 · Cited by 18

MET inhibition in lung cancer.

Menis, J., Levra, M. G., & Novello, S. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2012.12.04 · Cited by 17

Resistance to HER2-targeted therapies: a potential role for FOXM1

Peake, B. F., & Nahta, R. (2014) · Breast Cancer Management · doi:10.2217/bmt.14.33 · Cited by 18

Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic

Fabi, A., Mottolese, M., & Segatto, O. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1169-7 · Cited by 18

Src Mutation Induces Acquired Lapatinib Resistance in ERBB2-Amplified Human Gastroesophageal Adenocarcinoma Models

Hong, Y. S., Kim, J., Pectasides, E., Fox, C., Hong, S., Ma, Q., Wong, G. S., Peng, S., Stachler, M. D., Thorner, A. R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109440 · Cited by 18

HER2-Positive Breast Cancer Treatment and Resistance

Veeraraghavan, J., Angelis, C. D., Gutiérrez, C., Liao, F.-T., Sabotta, C. M., Rimawi, M. F., Osborne, C. K., & Schiff, R. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-70875-6_24 · Cited by 21

Current progress in chimeric antigen receptor-modified T cells for the treatment of metastatic breast cancer

Li, Y., Chen, G.-L., Xiang, Z., Liu, Y., Li, X., Bi, J.-W., & Wang, Q. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114648 · Cited by 19

Met Kinetic Signature Derived from the Response to HGF/SF in a Cellular Model Predicts Breast Cancer Patient Survival

Stein, G. Y., Yosef, N., Reichman, H., Horev, J., Laser-Azogui, A., Berens, A., Resau, J. H., Ruppin, E., Sharan, R., & Tsarfaty, I. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045969 · Cited by 17

Analysis of c‐Met Kinase Domain Complexes: A New Specific Catalytic Site Receptor Model for Defining Binding Modes of ATP‐Competitive Ligands

Asses, Y., Leroux, V., Taïri-Kellou, S., Dono, R., Maina, F., & Maigret, B. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00895.x · Cited by 17

Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive casesPreprint

Owen, D. R., Wong, H., Bonakdar, M., Jones, M. R., Hughes, C. S., Morin, G. B., Jones, S. J. M., Renouf, D. J., Lim, H. J., Laskin, J. J., et al. (2018) · Molecular Case Studies · doi:10.1101/mcs.a002535 · Cited by 17

HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line

Lee, H. J., Shin, S., Kang, J.-H., Han, K.-C., Kim, Y. H., Bae, J., & Park, K. H. (2020) · Cancers · doi:10.3390/cancers12092630 · Cited by 16

Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence

Martín, V., Corso, S., Comoglio, P. M., & Giordano, S. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.06.010 · Cited by 17

The coexpression and prognostic significance of c-MET, fibroblast growth factor receptor 2, and human epidermal growth factor receptor 2 in resected gastric cancer: a retrospective study

Jia, Y., Li, T., Zhang, D., Fan, Z.-M., Fan, H., Yan, J., Chen, L., Tang, H., Qin, Y., & Li, X. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s111778 · Cited by 16

New developments in the treatment of HER2-positive breast cancer

Nahta, R. (2012) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s24976 · Cited by 16

Calmodulin binds HER2 and modulates HER2 signaling

White, C. D., Li, Z., & Sacks, D. B. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.12.016 · Cited by 16

A new Met inhibitory-scaffold identified by a focused forward chemical biological screen

Patané, S., Pietrancosta, N., Hassani, H., Leroux, V., Maigret, B., Kraus, J., Dono, R., & Maina, F. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.159 · Cited by 18

The Significance of MET Expression and Strategies of Targeting MET Treatment in Advanced Gastric Cancer

Liao, H., Tian, T., Sheng, Y., Peng, Z., Li, Z., Wang, J., Li, Y., Zhang, C., & Gao, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719217 · Cited by 15

HER2-positive gastric cancer with paraaortic nodal metastasis successfully resected after chemotherapy with trastuzumab: a case report.

Ikari, N., Nakajima, G., Taniguchi, K., Sasagawa, T., Narumiya, K., Yamada, T., Kudo, K., Kitamura, Y., Hayashi, K., Nishikawa, T., et al. (2014) · PubMed · Cited by 15

Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells

Thaler, S., Schmidt, M., Roßwag, S., Thiede, G., Schad, A., & Sleeman, J. P. (2017) · Oncotarget · doi:10.18632/oncotarget.20261 · Cited by 15

ELOVL2-AS1 suppresses tamoxifen resistance by sponging miR-1233-3p in breast cancer

Kim, H. W., Baek, M., Jung, S., Jang, S., Lee, H., Yang, S., Kwak, B. S., & Kim, S. J. (2023) · Epigenetics · doi:10.1080/15592294.2023.2276384 · Cited by 14

Calpain4 is required for activation of HER2 in breast cancer cells exposed to trastuzumab and its suppression decreases survival and enhances response

Kulkarni, S., Saju, L., Farver, C. F., & Tubbs, R. (2012) · International Journal of Cancer · doi:10.1002/ijc.27510 · Cited by 14

Emerging strategies for the dual inhibition of HER2-positive breast cancer

Konecny, G. E. (2012) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e32835c5e90 · Cited by 14

Primary and acquired resistance to biologic therapies in gastrointestinal cancers

Lubner, S. J., Uboha, N. V., & Deming, D. A. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.01.16 · Cited by 14

Quantitative digital image analysis of tumor-infiltrating lymphocytes in HER2-positive breast cancer

Abe, N., Matsumoto, H., Takamatsu, R., Tamaki, K., Takigami, N. H., Uehara, K., Kamada, Y., Tamaki, N., Motonari, T., Unesoko, M., et al. (2019) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-019-02730-6 · Cited by 14

LMO4 mediates trastuzumab resistance in HER2 positive breast cancer cells.

Ding, K., Wu, Z., Li, X., Sheng, Y., Wang, X., & Tan, S. H. (2018) · Europe PMC (PubMed Central) · Cited by 14

Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib

Kourié, H. R., Rassy, E., Clatot, F., de Azambuja, E., & Lambertini, M. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s122397 · Cited by 14

ctDNA Analysis in ERBB2 -Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial

Meric‐Bernstam, F., Raghav, K. P. S., Sweeney, C. J., Swanton, C., Spigel, D. R., Bose, R., Burris, H. A., Friedman, C. F., Espenschied, C. R., Grindheim, J. M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2763 · Cited by 14

Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer

Park, J., Kang, S. K., Kwon, W. S., Jeong, I., Kim, T. S., Yu, S. Y., Cho, S. W., Chung, H. C., & Rha, S. Y. (2023) · Scientific Reports · doi:10.1038/s41598-023-49646-5 · Cited by 13

Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents.

Califano, R., Morgillo, F., de Mello, R. A., & Mountzios, G. (2015) · PubMed Central · doi:10.3978/j.issn.2305-5839.2015.03.44 · Cited by 13

Targeted approaches for HER2 breast cancer therapy: News from nanomedicine?

Mazzucchelli, S. (2014) · World Journal of Pharmacology · doi:10.5497/wjp.v3.i4.72 · Cited by 13

Pan-HER-targeted approach for cancer therapy: Mechanisms, recent advances and clinical prospect

Wang, M., Hu, Y., Yu, T., Ma, X., Wei, X., & Wei, Y. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.07.014 · Cited by 14

Emerging HER2-directed therapeutic agents for gastric cancer in early phase clinical trials

Lote, H., & Chau, I. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2030311 · Cited by 13

Differential role of MACC1 expression and its regulation of the HGF/c-Met pathway between breast and colorectal cancer

Sueta, A., Yamamoto, Y., Yamamoto‐Ibusuki, M., Hayashi, M., Takeshita, T., Yamamoto, S., Omoto, Y., & Iwase, H. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2907 · Cited by 13

Involvement of HER-2/neu and metastasis-related proteins in the development of ileal neuroendocrine tumors

Azzoni, C., Bottarelli, L., Cecchini, S., Lagrasta, C. A. M., Pizzi, S., D’Adda, T., Tamburini, E., Rindi, G., & Bordi, C. (2011) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-011-1069-y · Cited by 13

Genomic characterization between HER2 ‐positive and negative gastric cancer patients in a prospective trial

Hu, Q., Oki, E., Yamada, T., Kashiwada, T., Sonoda, H., Kataoka, M., Kawanaka, H., Tsuji, Y., Makiyama, A., Nakashima, Y., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6269 · Cited by 11

Gene silencing of c-Met leads to brain metastasis inhibitory effects

Lee, S. J., Seol, H. J., Lee, H. W., Kang, W. Y., Kang, B. G., Jin, J., Jo, M.-Y., Jin, Y., Lee, J.-I., Joo, K. M., et al. (2013) · Clinical & Experimental Metastasis · doi:10.1007/s10585-013-9584-7 · Cited by 12

MACC1 as a Potential Target for the Treatment and Prevention of Breast Cancer

Lv, M., Jiao, Y., Yang, B., Ye, M., Di, W., Su, W., & Zhong, J. (2023) · Biology · doi:10.3390/biology12030455 · Cited by 12

Emerging kinase inhibitors of the treatment of gastric cancer

Vincenzi, B., Imperatori, M., Silletta, M., Marrucci, E., Santini, D., & Tonini, G. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1051467 · Cited by 12

Role of trastuzumab in the management of HER2-positive metastatic breast cancer

Valabrega, G. (2010) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s6070 · Cited by 12

Combined Drug Action of 2-Phenylimidazo[2,1-b]Benzothiazole Derivatives on Cancer Cells According to Their Oncogenic Molecular Signatures

Furlan, A., Roux, B., Lamballe, F., Conti, F., Issaly, N., Daian, F., Guillemot, J.-F., Richelme, S., Contensin, M., Bosch, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046738 · Cited by 14

Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?

Troiani, T., Martinelli, E., Morgillo, F., Capasso, A., Nappi, A. G., Sforza, V., & Ciardiello, F. (2012) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012462462 · Cited by 12

Update on Clinical Trials: Genetic Targets in Breast Cancer

Lim, B., Cream, L., & Harvey, H. A. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-6176-0_2 · Cited by 11

Effective personalized therapy for breast cancer based on predictions of cell signaling pathway activation from gene expression analysis

Jhan, J.-R., & Andrechek, E. R. (2017) · Oncogene · doi:10.1038/onc.2016.503 · Cited by 11

Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines

Ebert, K., Zwingenberger, G., Barbaria, E., Keller, S., Heck, C., Arnold, R., Hollerieth, V., Mattes, J., Geffers, R., Raimúndez, E., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07540-7 · Cited by 11

Anticancer Potential of Hydroxychavicol Derived from Piper betle L: An in Silico and Cytotoxicity Study

Sekar, V., Gnanam, R., Caroline, R., Santhanakrishnan, V. P., & Kandavelmani, A. (2022) · Nutrition and Cancer · doi:10.1080/01635581.2022.2085310 · Cited by 11

The relevance of the intrinsic subtype to the clinicopathological features and biomarkers in Japanese breast cancer patients

Tamaki, M., Kamio, T., Kameoka, S., Kojimahara, N., & Nishikawa, T. (2013) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-11-293 · Cited by 11

ERα-related chromothripsis enhances concordant gene transcription on chromosome 17q11.1-q24.1 in luminal breast cancer

Lin, C.-L., Tan, X., Chen, M., Kusi, M., Hung, C., Chou, C., Hsu, Y., Wang, C., Kirma, N. B., Chen, C., et al. (2020) · BMC Medical Genomics · doi:10.1186/s12920-020-0729-7 · Cited by 11

A receptor-antibody hybrid hampering MET-driven metastatic spread

Modica, C., Basilico, C., Chiriaco, C., Borrelli, N., Comoglio, P. M., & Vigna, E. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01822-5 · Cited by 11

Acquired Substrate Preference for GAB1 Protein Bestows Transforming Activity to ERBB2 Kinase Lung Cancer Mutants

Fan, Y., Wong, L., Marino, M. P., Ou, W., Shen, Y., Wu, W. J., Wong, K., Reiser, J., & Johnson, G. R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.434217 · Cited by 11

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res

Shattuck, D. L., Miller, J. K., Carraway, K. L., III, & Sweeney, C. A. (2015)

Abstract 1821: HER3 activation by MET contributes to trastuzumab resistance in HER2-positive breast cancer

Hashimoto, K., Macaulay, V. M., & Kong, A. H. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-1821

HER3 activation by MET contributes to trastuzumab resistance in HER2-positive breast cancer

Hashimoto, K., Macaulay, V. M., & Kong, A. H. (2014) · Cancer Research

Metformin Enhances Trastuzumab Efficacy and Overcomes Resistance in HER2 Type Breast Cancer Cells.

Thor, A. D., Fan, Z., Yang, X., Esteva, F. J., Jones, F., Edgerton, S., Lind, S. M., & Liu, B. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-09-1133 · Cited by 2

The mechanism of HER2-amplified breast cancer with trastuzumab resistance and the research for novel therapy

Ren, Y. (2012) · Shengming kexue